{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:34:44Z","timestamp":1790505284829,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Glucose lowering agents that reduce the risk of major adverse cardiovascular events (MACE) would be considered a major advance. The reduction of cardiovascular risk by sodium-glucose cotransporter 2 inhibitors (SGLT-2i) has been confirmed by some large-scale randomized controlled studies (RCTs) and systematic reviews of RCTs, but exact indicators of cardiovascular risk remained controversial. Whether consistent results can be obtained in clinical practice is unclear. Therefore, in this meta-analysis, we analyzed the real-world effect of SGLT-2i on cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We did a real-world systematic review and meta-analysis of cardiovascular outcome of SGLT-2i in patients with T2DM. We searched PubMed and Embase for trials published up to October 23, 2019. Data search and extraction were completed with a standardized data form and any discrepancies were resolved by consensus. The primary outcome was MACE and all-cause mortality (ACM). Secondary outcomes were hospitalization for heart failure (HHF), atrial fibrillation (AF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), unstable angina (UA), heart failure (HF). Odds ratio (OR) with 95% CIs were pooled across trials, and cardiovascular outcomes were stratified by baseline incidence of cardiovascular disease (CVD), usage rate of cardiovascular benefit drug, follow-up period and region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen trials enrolling 3,157,259 patients were included. SGLT-2i reduced MACE (OR, 0.71; 95% CI 0.67,0.75, P&lt;0.001) and ACM (OR, 0.53; 95% CI 0.49,0.57, P&lt;0.001) compared to other glucose lowering drugs (oGLD). Compared with oGLD, SGLT-2i had significantly lowered the risk of HHF (OR, 0.56; 95% CI 0.46,0.68, P&lt;0.001), MI (OR, 0.77; 95% CI 0.73,0.81, P&lt;0.001), stroke (OR, 0.75; 95% CI 0.72,0.78, P&lt;0.001), CVM (OR, 0.58; 95% CI 0.49,0.69, P&lt;0.001) and HF (OR, 0.56; 95% CI 0.48,0.67, P&lt;0.001), but there was no benefit from UA or AF. SGLT-2i significantly reduced the risk of severe hypoglycemia (OR, 0.78; 95% CI 0.69,0.90, P&lt;0.001) and lower limb amputation (OR, 0.83; 95% CI 0.71,0.98, P&lt;0.001), but it may increase the risk of diabetic ketoacidosis. Subgroup analysis showed SGLT-2i reduced the risk of MACE, ACM, HHF, MI, stroke, CVM and HF with a similar benefit regardless of the incidence of CVD was (20\u201330)% or &lt; 15%, (15\u201330)% or &lt;15% have been treated with GLP-1 receptor agonists (GLP-1RA), &gt;80% or &lt;70% have been treated with statins or both GLP-1RA and statins. SGLT-2i reduced the risk of ACM in low-risk population (P&lt;0.001). No inconsistencies were found when stratification was performed at 1 or (3\u20134) years of follow-up except for BKA followed up for 1 year. SGLT-2i showed similar cardiovascular benefits in the Nordic countries, Asia and the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The predominant impact of SGLT-2i is on cardiovascular outcome driven predominantly by reduction in MACE, ACM, HHF, MI, stroke, CVM, HF, but not UA or AF. SGLT-2i has robust benefits on reducing MACE, ACM, HHF, MI, stroke, CVM and HF regardless of a history of usage rate of GLP-1RA and\/or statins and \/or metformin. SGLT-2i does not increase the risk of severe hypoglycemia and lower limb amputation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0244689","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T22:33:49Z","timestamp":1613774029000},"page":"e0244689","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":68,"title":["Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis"],"prefix":"10.1371","volume":"16","author":[{"given":"Chun-xing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-1318","authenticated-orcid":true,"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"issue":"4","key":"pone.0244689.ref001","doi-asserted-by":"crossref","first-page":"e11295","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"S Raghavan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"pone.0244689.ref002","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","article-title":"Diabetes mellitus and cardiovascular disease","volume":"39","author":"AM Schmidt","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"pone.0244689.ref003","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/jama.2019.2702","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"321","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"pone.0244689.ref004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis","volume":"18","author":"Y Han","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"pone.0244689.ref005","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"SJ Griffin","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"pone.0244689.ref006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"SP Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0244689.ref007","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S2213-8587(17)30012-8","article-title":"Semaglutide: a promising new glucagon-like peptide-1 receptor agonist","volume":"5","author":"AJ Scheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"pone.0244689.ref008","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"SP Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"pone.0244689.ref009","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"RR Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0244689.ref010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0244689.ref011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"SD Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0244689.ref012","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0244689.ref013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes\u2014a systematic review","volume":"140","author":"K Radholm","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"pone.0244689.ref014","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13300-019-0597-3","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events: a meta-analysis","volume":"10","author":"B Sinha","year":"2019","journal-title":"Diabetes Ther"},{"issue":"10166","key":"pone.0244689.ref015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"TA Zelniker","year":"2019","journal-title":"Lancet"},{"key":"pone.0244689.ref016","first-page":"1","volume":"2","author":"GA Wells","year":"2019","journal-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analysis"},{"issue":"2","key":"pone.0244689.ref017","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study","volume":"20","author":"F Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"pone.0244689.ref018","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jc.2016-3446","article-title":"All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database","volume":"102","author":"KA Toulis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"pone.0244689.ref019","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/dom.13532","article-title":"Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis","volume":"21","author":"A Cahn","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"pone.0244689.ref020","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study","volume":"71","author":"M Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"pone.0244689.ref021","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"KI Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"pone.0244689.ref022","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 Inhibitors in the real world)","volume":"137","author":"JA Udell","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"pone.0244689.ref023","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"GK Dawwas","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"pone.0244689.ref024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)","volume":"136","author":"M Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"22","key":"pone.0244689.ref025","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","article-title":"SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL","volume":"71","author":"MA Cavender","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"pone.0244689.ref026","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/dom.12889","article-title":"Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes","volume":"19","author":"T Nystrom","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"pone.0244689.ref027","doi-asserted-by":"crossref","first-page":"l4772","DOI":"10.1136\/bmj.l4772","article-title":"Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study","volume":"366","author":"B Pasternak","year":"2019","journal-title":"BMJ"},{"key":"pone.0244689.ref028","doi-asserted-by":"crossref","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study","volume":"360","author":"E Patorno","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"pone.0244689.ref029","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","article-title":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D)","volume":"20","author":"PB Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"pone.0244689.ref030","first-page":"S22","article-title":"Dapagliflozin is Associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic","volume":"41","author":"A Norhammar","year":"2017","journal-title":"Can J Diabetes"},{"issue":"5","key":"pone.0244689.ref031","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"MS Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"pone.0244689.ref032","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"SL Zheng","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"pone.0244689.ref033","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 Inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"HY Chang","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"12","key":"pone.0244689.ref034","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1111\/dom.13459","article-title":"Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study","volume":"20","author":"S Adimadhyam","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"pone.0244689.ref035","first-page":"46","article-title":"SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic","volume":"13","author":"J Sung","year":"2018","journal-title":"J Clin Transl Endocrinol"},{"key":"pone.0244689.ref036","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"P Ueda","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"pone.0244689.ref037","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13647","article-title":"Sodium-glucose cotransporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers","volume":"21","author":"JY Yang","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"pone.0244689.ref038","doi-asserted-by":"crossref","first-page":"e0234065","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis","volume":"15","author":"J Heyward","year":"2020","journal-title":"PLoS One"},{"key":"pone.0244689.ref039","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.diabres.2019.05.028","article-title":"Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials","volume":"153","author":"I Dicembrini","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"pone.0244689.ref040","doi-asserted-by":"crossref","first-page":"108136","DOI":"10.1016\/j.diabres.2020.108136","article-title":"Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials","volume":"163","author":"S Miyashita","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"pone.0244689.ref041","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A Multicenter Cohort Study","volume":"173","author":"A Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"pone.0244689.ref042","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials","volume":"130","author":"M Monami","year":"2017","journal-title":"Diabetes Res Clin Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T22:34:14Z","timestamp":1613774054000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0244689"}},"subtitle":[],"editor":[{"given":"Giuseppe","family":"Remuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0244689","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16511\/v1","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]}}}